Intravenous N-Acetylcysteine in the Prevention of Contrast Media-Induced Nephropathy

  • Spencer M Anderson
    Molecular Pharmacology and Biological Chemistry, Northwestern University, Argonne, IL; School of Pharmacy and Health Professions, Creighton University, Omaha, NE
  • Zoon H Park
    Department of Pharmacy Services, Swedish Covenant Hospital, Chicago, IL
  • Ramesh V Patel
    Department of Pharmacy Services, Swedish Covenant Hospital

書誌事項

公開日
2011-01
権利情報
  • https://journals.sagepub.com/page/policies/text-and-data-mining-license
DOI
  • 10.1345/aph.1p275
公開者
SAGE Publications

この論文をさがす

説明

<jats:sec><jats:title>Objective</jats:title><jats:p> Ti define the clinical role of intravenous N-acetylcysteine for prophylaxis of contrast-induced nephropathy (CIN). </jats:p></jats:sec><jats:sec><jats:title>Data Sources:</jats:title><jats:p> Randomized controlled clinical trials were identified using a search of MEDLINE (1990-September 2010) with the search terms acetylcysteine, N-acetylcysteine, NAC, intravenous, IV, nephropathy, nephrotoxic, radiocontrast, contrast, and media. The search was limited to studies published in English. Additional pertinent literature was retrieved by reviewing references of the articles obtained in the initial search. </jats:p></jats:sec><jats:sec><jats:title>Data Synthesis:</jats:title><jats:p> N-Acetylcysteine is a vasodilator and antioxidant that has been investigated for the prevention of CIN. In the majority of clinical trials, neither oral nor intravenous N-acetyIcysteine has demonstrated clinical benefits at preventing CIN. The pharmacodynamic and pharmacokinetic profiles of intravenous N-acetylcysteine are significantly different from those of the oral product in that intravenous administration bypasses extensive first-pass metabolism. Studies have suggested that N-acetylcysteine directly affects serum creatinine levels in a way that is not associated with improvement of kidney function. Only intravenous N-acetylcysteine doses that were higher than the oral doses showed potential benefits, but they were associated with significant adverse events. Furthermore, the study populations were heterogeneous, including patients with various levels of kidney function and other risk factors, and the clinical definition of CIN was not well established. </jats:p></jats:sec><jats:sec><jats:title>Conclusions:</jats:title><jats:p> NO conclusive evidence has shown that intravenous N-acetyl-cysteine is safe and effective in preventing CIN. Further clinical trials to define its role are warranted. </jats:p></jats:sec>

収録刊行物

被引用文献 (2)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ